Help us: Donate
Follow us on:
×

Tag: UNITY Biotechnology

June 05, 2020
Don’t let your birthday get you down and remind you that you are getting older; there are plenty of reasons to be cheerful about the future and your place in it, especially as science is now turning its attention to aging. Another trip around the sun So here I am again, another birthday just gone...
January 24, 2020
The Longevity Therapeutics conference enters its second year, opening its doors on January 28th for a three-day event focused on aging research. If you are interested in the actual science happening in the field with no snake oil in sight, then this is the West Coast conference to attend. With over 80 speakers, including researchers,...
June 19, 2019
Recently, Unity Biotechnology completed a phase 1 trial of its drug UBX0101. While the trial found that the drug was non-toxic and lacked serious side effects, many of its results were not statistically significant. UBX0101 UBX0101 aims to treat osteoarthritis and possibly other diseases of aging through directly targeting one of the aspects of aging...
March 22, 2019
On July 11-12th, we return to the Cooper Union in New York City for our second annual Ending Age-Related Diseases conference, which focuses on the progress in aging research as well as the business side of biotech. We will be bringing you the latest aging research, investment, and business knowledge from some of the top...
January 29, 2019
UNITY Biotechnologies has recently announced an expansion of its first-stage human trial of UBX0101, a drug that has been shown to have senolytic properties in mice [1] and that the company hopes will be useful in treating painful osteoarthritis of the knee. An expanded clinical trial UNITY Biotechnologies, a $495 million biotech company in the...
January 14, 2019
Another senolytic drug candidate has entered development at Unity Biotechnologies. The purpose of senolytics is to clear the body of harmful senescent cells, which accumulate with age and encourage age-related diseases to develop. A new treatment for age-related diseases of the eye Recently, UNITY Biotechnologies announced the selection of a new lead drug, UBX1967, with...